Bones in Multiple Myeloma

Imaging and Therapy

Elena Zamagni, Michele Cavo, Bita Fakhri, Ravi Vij, G. David Roodman

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Bone disease is the most frequent disease-defining clinical feature of multiple myeloma (MM), with 90% of patients developing bone lesions over the course of their disease. For this reason, imaging plays a major role in the management of disease in patients with MM. Although conventional radiography has traditionally been the standard of care, its low sensitivity in detecting osteolytic lesions has called for more advanced imaging modalities. In this review, we discuss the advantages, indications, and applications of whole-body low-dose CT (WBLDCT), 18F-fluorodeoxyglucose (FDG)-PET/CT, MRI, and other novel imaging modalities in the management of disease in patients with plasma cell dyscrasias. We also review the state of the art in treatment of MM bone disease (MMBD) and the role of bisphosphonates and denosumab, a monoclonal antibody that binds and blocks the activity of receptor activator of nuclear factor-kappa B ligand (RANKL), which was recently approved by the U.S. Food and Drug Administration for MMBD.

Original languageEnglish (US)
Pages (from-to)638-646
Number of pages9
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Issue number38
DOIs
StatePublished - May 23 2018

Fingerprint

Bone Diseases
Multiple Myeloma
Disease Management
Bone and Bones
RANK Ligand
Paraproteinemias
Fluorodeoxyglucose F18
Diphosphonates
United States Food and Drug Administration
Standard of Care
Radiography
Therapeutics
Monoclonal Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bones in Multiple Myeloma : Imaging and Therapy. / Zamagni, Elena; Cavo, Michele; Fakhri, Bita; Vij, Ravi; Roodman, G. David.

In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, No. 38, 23.05.2018, p. 638-646.

Research output: Contribution to journalReview article

@article{6582ef5af10644169c36460bd1fdb46b,
title = "Bones in Multiple Myeloma: Imaging and Therapy",
abstract = "Bone disease is the most frequent disease-defining clinical feature of multiple myeloma (MM), with 90{\%} of patients developing bone lesions over the course of their disease. For this reason, imaging plays a major role in the management of disease in patients with MM. Although conventional radiography has traditionally been the standard of care, its low sensitivity in detecting osteolytic lesions has called for more advanced imaging modalities. In this review, we discuss the advantages, indications, and applications of whole-body low-dose CT (WBLDCT), 18F-fluorodeoxyglucose (FDG)-PET/CT, MRI, and other novel imaging modalities in the management of disease in patients with plasma cell dyscrasias. We also review the state of the art in treatment of MM bone disease (MMBD) and the role of bisphosphonates and denosumab, a monoclonal antibody that binds and blocks the activity of receptor activator of nuclear factor-kappa B ligand (RANKL), which was recently approved by the U.S. Food and Drug Administration for MMBD.",
author = "Elena Zamagni and Michele Cavo and Bita Fakhri and Ravi Vij and Roodman, {G. David}",
year = "2018",
month = "5",
day = "23",
doi = "10.1200/EDBK_205583",
language = "English (US)",
pages = "638--646",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",
number = "38",

}

TY - JOUR

T1 - Bones in Multiple Myeloma

T2 - Imaging and Therapy

AU - Zamagni, Elena

AU - Cavo, Michele

AU - Fakhri, Bita

AU - Vij, Ravi

AU - Roodman, G. David

PY - 2018/5/23

Y1 - 2018/5/23

N2 - Bone disease is the most frequent disease-defining clinical feature of multiple myeloma (MM), with 90% of patients developing bone lesions over the course of their disease. For this reason, imaging plays a major role in the management of disease in patients with MM. Although conventional radiography has traditionally been the standard of care, its low sensitivity in detecting osteolytic lesions has called for more advanced imaging modalities. In this review, we discuss the advantages, indications, and applications of whole-body low-dose CT (WBLDCT), 18F-fluorodeoxyglucose (FDG)-PET/CT, MRI, and other novel imaging modalities in the management of disease in patients with plasma cell dyscrasias. We also review the state of the art in treatment of MM bone disease (MMBD) and the role of bisphosphonates and denosumab, a monoclonal antibody that binds and blocks the activity of receptor activator of nuclear factor-kappa B ligand (RANKL), which was recently approved by the U.S. Food and Drug Administration for MMBD.

AB - Bone disease is the most frequent disease-defining clinical feature of multiple myeloma (MM), with 90% of patients developing bone lesions over the course of their disease. For this reason, imaging plays a major role in the management of disease in patients with MM. Although conventional radiography has traditionally been the standard of care, its low sensitivity in detecting osteolytic lesions has called for more advanced imaging modalities. In this review, we discuss the advantages, indications, and applications of whole-body low-dose CT (WBLDCT), 18F-fluorodeoxyglucose (FDG)-PET/CT, MRI, and other novel imaging modalities in the management of disease in patients with plasma cell dyscrasias. We also review the state of the art in treatment of MM bone disease (MMBD) and the role of bisphosphonates and denosumab, a monoclonal antibody that binds and blocks the activity of receptor activator of nuclear factor-kappa B ligand (RANKL), which was recently approved by the U.S. Food and Drug Administration for MMBD.

UR - http://www.scopus.com/inward/record.url?scp=85056044415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056044415&partnerID=8YFLogxK

U2 - 10.1200/EDBK_205583

DO - 10.1200/EDBK_205583

M3 - Review article

SP - 638

EP - 646

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

IS - 38

ER -